Archives: Research Projects
Epigenetic Causes of Acquired Resistance of Anti-VEGF Therapy
The major reported cause of ovarian cancer mortality is resistance to conventional chemotherapies which in turn promotes cancer metastasis…
Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. There are about 20,000 new cases per year and only 46% of those women survive five years…
Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments
Ovarian carcinoma claims the lives of more than 14,000 American women every year. It is often detected at late stages and the standard treatment based on surgery and chemotherapy have met with very limited success during the past 40 years…
Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
More than 22,000 women develop ovarian cancer each year in the United States. Despite substantial improvements in surgery and chemotherapy, the disease still proves lethal in 70% of cases…
Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer
Cancers typically develop from a single cell that proliferates and expands in space and time. Modeling the process of clonal evolution in cancer may enable the prediction of progression and response to therapy…
Precision Medicine in Ovarian Cancer: Using Single Cell Analysis
Despite progress in the understanding of tumor biology, clinical trials designed using specialized new therapies against specific biologic and genetic changes in patient’s tumors commonly fail…
The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells
Cancer cells display uncontrollable growth and high genetic instability…
Chromatin Remodeling and Immunotherapy in Ovarian Cancer
Cancer immunotherapies such as drugs targeting the immune inhibitory molecules known as PD-1 and PD-L1 have shown benefit across a number of cancers. Unfortunately, in ovarian cancer, only a small fraction of patients responds to such treatments…
Tumor-Derived Extracellular Vesicle in Ovarian Cancer
If ovarian cancer takes decades to develop, why are we still unable to detect the disease at an early stage when surgery is curative? Only recently have scientist demonstrated that many of the most common and deadly ovarian cancers actually do not…
Profiling Co-Evolution of Ovarian Cancer and its Immune Microenvironment
Women with high grade serous ovarian cancer HGSOC represent 70% of all ovarian cancers and suffer high morbidities and poor response to standard of care treatment. The five-year survival rate after diagnosis is <50%…
Interplay Between Ovarian Cancer Stem Cells and the Tumor Microenvironment
The aim of this project is to find new treatments for the most common type of ovarian cancer, high-grade serous ovarian cancer…
Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma
Cancer surgery and chemotherapy can be life-saving, however for some cancers, they may also cause the development of future metastases…